Clinical Nurse Specialist in Leominster, MA Accepting Medicare

5 Clinical Nurse Specialist nurses found. Showing 1 - 5

Dr. Ann Galligan, ED D RN CS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 25 Mohawk Drive, Leominster, MA 01453 Phone: 978-840-1100    Fax: 508-792-1514

Ms. Barbara J Laforce, F.N.P. Clinical Nurse Specialist - Family Health Medicare: Medicare Enrolled Practice Location: 14 Manning Ave, Leominster, MA 01453 Phone: 978-878-8145

Donna R Santimore, PMHCNS - BC Clinical Nurse Specialist - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 40 Spruce St, Leominster, MA 01453 Phone: 978-534-6116    Fax: 978-534-3294

Elzira A Deoliveira, PCNS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Accepting Medicare Assignments Practice Location: 40 Spruce Street, Leominster, MA 01453 Phone: 800-977-5555

Ms. Tammy Zaruba, CPNP Clinical Nurse Specialist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 100 Hospital Rd Ste 4, Medical Associates Pediatrics, Leominster, MA 01453 Phone: 978-514-6300    Fax: 978-514-6324

News Archive

Sample list of attainable New Year's resolutions

New Year's resolutions are full of clichés and empty promises but a clinical psychologist at Wake Forest Baptist Medical Center has some sound advice that might just help a little.

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis.

Researchers report how a popular antidepressant drug could rewire the brain

Prozac, the trade name for the drug fluoxetine, was introduced to the U.S. market for the treatment of depression in 1988.

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its naloxone lotion for the topical treatment of pruritus accompanying cutaneous t-cell lymphoma (CTCL, also known as mycosis fungoides).

Read more Medical News

› Verified 9 days ago